

THERAPEUTICS FOR WOMEN'S HEALTH: TECHNOLOGIES AND GLOBAL MARKETS



BIO043E
May 2014

Dr. Ritu Thakur Dangi
Project Analyst

ISBN: 1-56965-811-0

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY BACKGROUND	2
STUDY GOALS AND OBJECTIVES	2
INTENDED AUDIENCE	4
SCOPE OF THE REPORT	4
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2012-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW OF WOMEN'S HEALTH DISORDERS	10
DISEASE OVERVIEW AND DEFINITIONS	10
<i>TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2018 (MILLIONS)</i>	11
<i>FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2012 (% OF TOTAL GENERAL FEMALE POPULATION)</i>	11
HISTORICAL BACKGROUND	12
AGING AND WOMEN'S HEALTH DISORDERS	13
<i>FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2012 (%)</i>	13
NEW USE FOR CONTRACEPTIVES	15
WOMEN AND SEXUAL HEALTH	17
FEMALE SEXUAL AROUSAL DISORDER	17
FEMALE ORGASMIC DISORDER	18
VAGINISMUS	18
INFERTILITY AND CANCER	18
CHAPTER 4 MENOPAUSE-RELATED SYMPTOMS AND DISEASES	20
OVERVIEW	20
ETIOLOGY	21
EPIDEMIOLOGY AND ECONOMIC BURDEN	21
<i>TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)</i>	21
<i>FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)</i>	21
<i>FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2012-2018 (MILLIONS)</i>	22

TOPIC	PAGE NO.
<i>FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012 (% OF GENERAL FEMALE POPULATION)</i>	23
SYMPTOMS OF MENOPAUSE	23
RISK FACTORS FOR EARLY ONSET MENOPAUSE	24
DIAGNOSIS AND TREATMENT	25
DIAGNOSIS OF MENOPAUSE	25
TREATMENT OPTIONS	26
<i>TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE</i>	26
Premarin (Conjugated Estrogens)	27
Prempro (Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)	28
Vagifem (Estradiol Vaginal Tablets)	28
Femring (Estradiol Acetate Vaginal Ring)	28
ISSUES ASSOCIATED WITH HORMONE THERAPY	29
REDUCING THE RISK OF EARLY MENOPAUSE	29
CHAPTER 5 POSTMENOPAUSAL OSTEOPOROSIS	32
DISEASE OVERVIEW	32
HUMAN BONE STRUCTURE	32
EPIDEMIOLOGY AND ECONOMIC BURDEN	33
<i>TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)</i>	34
<i>FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)</i>	34
<i>FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS)</i>	34
<i>FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)</i>	35
DISEASE SYMPTOMS AND RISK FACTORS	37
DISEASE SYMPTOMS	37
Fractures	37
Spinal Deformities	37
Pain	37
RISK FACTORS	37
DIAGNOSIS AND TREATMENT	39
DIAGNOSIS OF POSTMENOPAUSAL OSTEOPOROSIS	39
TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS	39
Bisphosphonates	40
Hormone Therapy	41
Selective Estrogen Receptor Modulators	41
Calcitonin	42
Parathyroid Hormone	42
<i>TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS</i>	43
Fosamax (Alendronate Sodium)	43
Actonel (Risedronate Sodium)	44
Evista (Raloxifene Hydrochloride)	45

TOPIC	PAGE NO.
Boniva (Ibandronate Sodium)	46
Forteo (Teriparatide (rDNA Origin)) Injection	46
Reclast (Zoledronate)	47
Calcitonin (Calcimar, Miacalcin)	47
Forteo (Teriparatide)	48
Aprala (Bazedoxifene/Conjugated Estrogen)	48
Viviant (Bazedoxifene)	48
REDUCING THE RISK OF OSTEOPOROSIS	49
CHAPTER 6 ENDOMETRIOSIS	52
DISEASE OVERVIEW	52
ETIOLOGY AND PATHOPHYSIOLOGY	53
DISEASE SYMPTOMS AND RISK FACTORS	54
PELVIC PAIN	54
DIFFICULTY BECOMING PREGNANT	55
ENDOMETRIOMAS	55
RISK FACTORS	55
Genetic Factors	55
Delayed Pregnancy	55
Age	56
Dietary Factors	56
STAGES OF ENDOMETRIOSIS	56
EPIDEMIOLOGY AND ECONOMIC BURDEN	57
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	58
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	58
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS)	59
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)	59
DIAGNOSIS AND TREATMENT	60
DIAGNOSIS OF ENDOMETRIOSIS	60
Pelvic Exam	61
Laparoscopy	61
Other Diagnostic Procedures	61
TREATMENT OPTIONS FOR ENDOMETRIOSIS	62
Pharmacological Treatment	62
NSAIDs	62
Hormonal Birth Control Treatments	63
Progestins	64
Gonadotropin Releasing Hormone Agonists	64
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS	65
Zoladex	65
Lupron Depot (Leuprolide Acetate)	66
Synarel (Nafarelin Acetate)	66
Danazol	66
Visanne	66

TOPIC	PAGE NO.
Surgery	67
LOWERING THE RISK OF ENDOMETRIOSIS	68
CHAPTER 7 POLYCYSTIC OVARY SYNDROME	70
DISEASE OVERVIEW	70
ETIOLOGY	70
EPIDEMIOLOGY AND ECONOMIC BURDEN	71
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	72
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	72
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2012-2018 (MILLIONS)	72
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)	73
DISEASE SYMPTOMS AND RISK FACTORS	74
DIAGNOSIS AND TREATMENT	75
DIAGNOSIS OF PCOS	75
Medical History and Physical Examination	75
Pelvic Examination	75
Laboratory Testing	75
Imaging Tests	76
TREATMENT OPTIONS FOR POLYCYSTIC OVARY SYNDROME	76
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME	77
Medications	78
Clomid (Clomiphene)	78
Vaniqa (Eflornithine)	79
Glucophage (Metformin)	79
Actos (Pioglitazone) and Avandia (Rosiglitazone)	79
Aldactone (Spironolactone)	79
Precose (Acarbose)	79
Apri (Desogestrel/Ethinyl Estradiol)	79
Propecia (Finasteride)	80
Eulexin (Flutamide)	80
Femara (Letrozole)	80
REDUCING THE RISK OF PCOS	80
CHAPTER 8 WOMEN'S HEALTH DISORDER THERAPEUTICS MARKET ASSESSMENT	82
GLOBAL WOMEN'S HEALTH MARKET	82
FIGURE 15 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	82
FIGURE 16 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2012-2018 (\$ MILLIONS)	83
FIGURE 17 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2012 (%)	84
FIGURE 18 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDER, 2012-2018 (\$)	85
ENDOMETRIOSIS	86

TOPIC	PAGE NO.
<i>FIGURE 19 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)</i>	86
MENOPAUSE	87
<i>FIGURE 20 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)</i>	87
POSTMENOPAUSAL OSTEOPOROSIS	88
<i>FIGURE 21 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)</i>	88
POLYCYSTIC OVARY SYNDROME	90
<i>FIGURE 22 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)</i>	90
ANNUAL COST OF THERAPY	91
<i>FIGURE 23 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2012-2018 (\$)</i>	91
GENERICS VERSUS BRANDED	92
<i>FIGURE 24 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2012 (%)</i>	93
MARKET GROWTH DRIVERS AND RESTRAINTS	93
Growth Drivers for Menopause-Related Conditions	93
Aging Female Population	93
Growth Restraints for Menopause	94
Low Rate of Prescriptions for Hormone Therapy	94
Availability of Alternative Treatment Options	94
Lack of Safe and Efficacious Drug	94
Growth Drivers for Endometriosis	94
Increasing Awareness	94
Growth Restraints for Endometriosis	95
Poor Diagnosis	95
Absence of Non-hormonal Therapy	95
Growth Drivers for Postmenopausal Osteoporosis	96
Increasing Disease Population	96
Sedentary Lifestyle	96
Growth Restraints for Postmenopausal Osteoporosis	96
Poor Diagnosis	96
Growth Drivers for PCOS	97
Growing Treated Population	97
Growth Restraints for PCOS	97
Unavailability of Novel Drugs	97
CHAPTER 9 COMPETITION AND MARKET SHARES	99
<i>TABLE 10 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2012 (\$ MILLIONS/%)</i>	99
<i>FIGURE 25 GLOBAL MARKET LEADER SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET, 2012 (%)</i>	99
CHAPTER 10 MARKET STRATEGY	102
<i>TABLE 11 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET</i>	102
MERGERS AND ACQUISITIONS	103
ACTAVIS' ACQUISITION OF WARNER CHILCOTT	103

TOPIC	PAGE NO.
AMGEN'S ACQUISITION OF MUSTAFA NEVZAT (MN) PHARMACEUTICALS	103
VALEANT PHARMACEUTICALS' ACQUISITION OF INOVA	103
TAKEDA'S ACQUISITION OF NYCOMED	104
TEVA PHARMACEUTICAL'S ACQUISITION OF THERAMEX	104
THERAPEUTICSMD'S ACQUISITION OF VITAMEDMD	104
SANOFI-AVENTIS' ACQUISITION OF BMP SUNSTONE	104
ABBOTT'S ACQUISITION OF SOLVAY PHARMACEUTICALS	105
FERRING PHARMACEUTICALS' ACQUIRED GLOBAL RIGHTS TO LYSTEDA FROM XANODYNE PHARMACEUTICALS	105
BIOSANTE ACQUIRED ELESTRIN ROYALTY FROM AZUR PHARMA	105
TEVA-KOWA PHARMA ACQUIRED MAJORITY STAKE IN TAISHO PHARMACEUTICAL	106
SCIELE PHARMA'S ACQUISITION OF ADDRENEX PHARMACEUTICALS	106
WARNER CHILCOTT'S ACQUISITION OF PROCTER & GAMBLE'S PRESCRIPTION DRUG BUSINESS	106
BIOSANTE PHARMACEUTICALS MERGES WITH CELL GENESYS	107
HISAMITSU PHARMACEUTICAL'S ACQUISITION OF NOVEN PHARMACEUTICALS	107
PFIZER'S ACQUISITION OF WYETH	107
PAR PHARMACEUTICALS' ACQUISITION OF MDRNA'S CALCITONIN ASSETS AND MANUFACTURING FACILITY	107
CHAPTER 11 DRUG PIPELINE ANALYSIS	110
<i>TABLE 12 PIPELINE DRUGS IN WOMEN'S HEALTH</i>	110
DRUGS UNDER DEVELOPMENT	112
TAK-385 (RELUGOLIX)	112
Description	112
Safety/Efficacy	112
Clinical Trials	112
ELAGOLIX	113
Description	113
Safety/Efficacy	113
Clinical Trials	114
ASP1707	115
Description	115
Clinical Trials	115
PROELLEX (TELAPRISTONE ACETATE) (6 MG AND 12 MG, LOW DOSE ORAL)	116
Description	116
Safety/Efficacy	116
Low Dose Oral Study	117
Vaginal Administration	117
PGL2001 (PGL2)	118
Description	118
Safety/Efficacy	118
Clinical Trials	118
PGL5001 (PGL5) (BENTAMAPIMOD/PROOF OF CONCEPT)	118
Description	118
Clinical Trials	119

TOPIC	PAGE NO.
KLH-2109	119
Description	119
Clinical Trials	119
AUS-131 (S-EQUOL)	119
Description	119
Safety/Efficacy	119
Clinical Trials	120
MPI-676 AND MPI-674 (FEMATHINA)	120
Description	120
Clinical Trials	121
17HSD1 (17-BETA-HYDROXYSTEROID DEHYDROGENASE 1)	121
Description	121
Safety/Efficacy	122
Clinical Trials	122
FEMITRA (ACOLBIFENE + DHEA (ORAL) + GNRH AGONIST) (SUBCUTANEOUS)	122
Description	122
BAY 1026153	123
Description	123
MK-0822 (ODANACATIB)	123
Description	123
Safety and Efficacy	123
Clinical Trials	123
MENERBA	124
Description	124
Safety/Efficacy	125
Clinical Trials	125
SEALA	126
Description	126
Clinical Trials	126
BA058-SC (ABALOPARATIDE)	127
Description	127
Safety/Efficacy	127
Clinical Trials	127
BA058-TD (TRANSDERMAL DELIVERY)	129
Description	129
Safety/Efficacy	129
Clinical Trials	130
RAD1901	130
Description	130
Safety/Efficacy	131
Clinical Trials	131
ZP-PTH (TERIPARATIDE)	132
Description	132
Safety/Efficacy	132
Clinical Trials	132
RECOMBINANT ORAL SALMON CALCITONIN	133
Description	133

TOPIC	PAGE NO.
Safety/Efficacy	133
Clinical Trials	133
ESN364	134
Description	134
Safety/Efficacy	134
Clinical Trials	134
VAGINORM	134
Description	134
Clinical Trials	135
AZD4901	135
Description	135
Clinical Trials	135
ESTRADIOL + TESTOSTERONE GEL	135
Description	135
AMG 785/CDP7851 (ROMOSUZUMAB)	135
Description	135
Safety/Efficacy	136
Clinical Trials	136
TX 12-001HR (17B ESTRADIOL + PROGESTERONE)	137
Description	137
Clinical Trials	137
CHAPTER 12 REGULATORY STRUCTURE	139
UNITED STATES	139
EUROPE	140
REGULATORY PROCEDURES	141
National Authorization Procedure	141
Centralized Procedure	141
Decentralized Procedure	141
Mutual Recognition Procedure	141
JAPAN	141
CHAPTER 13 PRICING AND REIMBURSEMENT	145
UNITED STATES	145
EUROPE	147
JAPAN	148
CHAPTER 14 CONCLUSIONS-OUTLOOK FOR WOMEN'S HEALTH THERAPEUTICS	150
MAJOR DEVELOPMENTS TO INFLUENCE MARKET	150
THERAPEUTIC DEVELOPMENTS	150
DEMOGRAPHIC AND ECONOMIC TRENDS	151
Increasing Aging Population	151
<i>TABLE 13 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)</i>	152
<i>FIGURE 26 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)</i>	152
<i>TABLE 14 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)</i>	153

TOPIC	PAGE NO.
<i>FIGURE 27 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	153
<i>TABLE 15 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	154
<i>FIGURE 28 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	154
<i>TABLE 16 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	155
<i>FIGURE 29 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	155
<i>TABLE 17 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	156
<i>FIGURE 30 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)</i>	156
Income Growth in Developing Markets	156
<i>TABLE 18 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE)</i>	157
TRENDS IN REIMBURSEMENT	157
FUTURE OUTLOOK	158
CHAPTER 15 APPENDIX A: COMPANY PROFILES	160
ABBVIE	160
ACTAVIS	160
AMGEN	161
ASAHI KASAI	162
ASTRAZANECA	162
ASTELLAS PHARMA INC.	163
BAYER	163
BIONOVO	164
CHUGAI PHARMACEUTICALS	165
DEPOMED INC.	165
ELI LILLY	166
ENDOCEUTICS	166
FORENDO PHARMA OY	167
IPSEN SA	168
LES LABORATORIES SERVIER SAS	168
MERCK	169
MOCHIDA PHARMA CO. LTD.	170
MEDITRINA PHARMACEUTICALS INC.	170
NOVARTIS AG	171
NOVO NORDISK A/S	172
NOVOGYNE PHARMACEUTICALS	173
NEUROCRINE BIOSCIENCES INC.	173
ORION PHARMA LTD.	173
PALADIN LABS INC.	174
PFIZER INC.	174
PREGLEM SA	176
ROCHE	176
RADIUS HEALTH INC.	177
REPROS THERAPEUTICS INC.	178
TAKEDA PHARMACEUTICAL	178
TEVA PHARMACEUTICAL INDUSTRIES	178

TOPIC	PAGE NO.
TSUMURA & CO.	179
TARSA THERAPEUTICS INC.	180
THERAPEUTICSMD	180
WARNER CHILCOTT CORP.	180
ZOSANO PHARMA INC.	181
CHAPTER 16 APPENDIX B: INDUSTRY AND PROFESSIONAL ORGANIZATIONS	184
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM)	184
ANDROGEN EXCESS AND PCOS SOCIETY	184
ASIA-PACIFIC MENOPAUSE FEDERATION	184
ENDOMETRIOSIS ASSOCIATION	184
ENDOMETRIOSIS FOUNDATION OF AMERICA (EFA)	184
ENDOMETRIOSIS.ORG	185
ENDOMETRIOSIS RESEARCH CENTRE (ERC)	185
ENDOMETRIOSIS U.K.	185
EUROPEAN ENDOMETRIOSIS LEAGUE (EEL)	185
EUROPEAN MENOPAUSE AND ANDROPAUSE SOCIETY (EMAS)	186
EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY (ESHRE)	186
FOOD AND DRUG ADMINISTRATION (FDA)	186
HORMONE FOUNDATION	186
INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS (IFPMA)	187
INTERNATIONAL MENOPAUSE SOCIETY (IMS)	187
INTERNATIONAL OSTEOPOROSIS FOUNDATION (IOF)	187
JAPAN ENDOMETRIOSIS ASSOCIATION (JEMA)	187
JAPAN SOCIETY FOR MENOPAUSE AND WOMEN'S HEALTH	188
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION (NCBI)	188
NATIONAL INSTITUTE ON AGING (NIA)	188
NORTH AMERICAN MENOPAUSE SOCIETY (NAMS)	188
NATIONAL OSTEOPOROSIS FOUNDATION (NOF)	189
NATIONAL WOMEN'S HEALTH INFORMATION CENTER (NWHIC)	189
PCOSUPPORT	189
WORLD ENDOMETRIOSIS RESEARCH FOUNDATION (WERF)	189
CHAPTER 17 APPENDIX C: ACTIVE CLINICAL TRIALS	191
<i>TABLE 19 ENDOMETRIOSIS TRIALS</i>	191
<i>TABLE 20 MENOPAUSE TRIALS</i>	192
<i>TABLE 21 POLYCYSTIC OVARY SYNDROME (PCOS) TRIALS</i>	194
<i>TABLE 22 POST MENOPAUSAL OSTEOPOROSIS TRIALS</i>	195
CHAPTER 18 APPENDIX D: ABBREVIATIONS	200
ABBREVIATIONS	200

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 GLOBAL GENERAL FEMALE POPULATION VS POPULATION SUFFERING FROM A WOMEN'S DISORDER, THROUGH 2018 (MILLIONS)	11
TABLE 2 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	21
TABLE 3 COMMONLY PRESCRIBED DRUGS USED TO TREAT THE SYMPTOMS OF MENOPAUSE	26
TABLE 4 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	34
TABLE 5 COMMONLY PRESCRIBED DRUGS USED TO TREAT POSTMENOPAUSAL OSTEOPOROSIS	43
TABLE 6 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	58
TABLE 7 DRUGS COMMONLY USED TO TREAT ENDOMETRIOSIS	65
TABLE 8 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC REGION, THROUGH 2018 (MILLIONS)	72
TABLE 9 COMMONLY PRESCRIBED GENERIC DRUGS FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME	77
TABLE 10 LEADING COMPANIES IN THE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2012 (\$ MILLIONS/%)	99
TABLE 11 KEY MERGERS/ACQUISITIONS WITHIN THE WOMEN'S HEALTH MARKET	102
TABLE 12 PIPELINE DRUGS IN WOMEN'S HEALTH	110
TABLE 13 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)	152
TABLE 14 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)	153
TABLE 15 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	154
TABLE 16 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	155
TABLE 17 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	156
TABLE 18 PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE)	157
TABLE 19 ENDOMETRIOSIS TRIALS	191
TABLE 20 MENOPAUSE TRIALS	192
TABLE 21 POLYCYSTIC OVARY SYNDROME (PCOS) TRIALS	194
TABLE 22 POST MENOPAUSAL OSTEOPOROSIS TRIALS	195

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR WOMEN'S HEALTH THERAPEUTICS, 2012-2018 (\$ MILLIONS)	7
FIGURE 1 DISTRIBUTION OF GLOBAL POPULATION SUFFERING FROM A WOMEN'S DISORDER BY TYPE, 2012 (% OF TOTAL GENERAL FEMALE POPULATION)	11
FIGURE 2 FEMALE LIKELIHOOD OF BECOMING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2012 (%)	13
FIGURE 3 GLOBAL PREVALENCE OF MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	21
FIGURE 4 GLOBAL POPULATION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS VS THE GENERAL FEMALE POPULATION, 2012-2018 (MILLIONS)	22
FIGURE 5 GLOBAL DISTRIBUTION OF FEMALES SUFFERING FROM MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012 (% OF GENERAL FEMALE POPULATION)	23
FIGURE 6 GLOBAL PREVALENCE OF POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	34
FIGURE 7 GLOBAL POPULATION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS VS THE OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS)	34
FIGURE 8 GLOBAL DISTRIBUTION OF FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)	35
FIGURE 9 PREVALENCE OF ENDOMETRIOSIS BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	58
FIGURE 10 GLOBAL ENDOMETRIOSIS POPULATION VS OVERALL FEMALE POPULATION, 2012-2018 (MILLIONS)	59
FIGURE 11 GLOBAL DISTRIBUTION OF ENDOMETRIOSIS POPULATION BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)	59
FIGURE 12 PREVALENCE OF POLYCYSTIC OVARY SYNDROME BY GEOGRAPHIC REGION, 2012-2018 (MILLIONS)	72
FIGURE 13 GLOBAL POLYCYSTIC OVARY SYNDROME DISEASE POPULATION VS FEMALE POPULATION, 2012-2018 (MILLIONS)	72
FIGURE 14 GLOBAL DISTRIBUTION OF POLYCYSTIC OVARY SYNDROME POPULATION BY GEOGRAPHIC REGION, 2012 (% OF FEMALE POPULATION)	73
FIGURE 15 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	82
FIGURE 16 GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2012-2018 (\$ MILLIONS)	83
FIGURE 17 GLOBAL MARKET SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET BY DISORDER TYPE, 2012 (%)	84
FIGURE 18 AVERAGE ANNUAL COST OF THERAPY FOR WOMEN'S HEALTH DISORDER, 2012-2018 (\$)	85
FIGURE 19 GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	86
FIGURE 20 GLOBAL MARKET FOR THERAPEUTICS TO TREAT MENOPAUSE-RELATED CONDITIONS BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	87
FIGURE 21 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS THERAPEUTICS MARKET BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	88
FIGURE 22 GLOBAL MARKET FOR POLYCYSTIC OVARY SYNDROME THERAPEUTICS BY GEOGRAPHIC REGION, 2012-2018 (\$ MILLIONS)	90
FIGURE 23 GLOBAL AVERAGE ANNUAL COST OF THERAPY BY DISORDER, 2012-2018 (\$)	91
FIGURE 24 GLOBAL SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET: BRANDED VS. GENERIC, 2012 (%)	93

FIGURE TITLE	PAGE NO.
FIGURE 25 GLOBAL MARKET LEADER SHARES OF WOMEN'S HEALTH THERAPEUTICS MARKET, 2012 (%)	99
FIGURE 26 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)	152
FIGURE 27 PROJECTED GLOBAL FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	153
FIGURE 28 PROJECTED U.S. FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	154
FIGURE 29 PROJECTED EUROPEAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	155
FIGURE 30 PROJECTED JAPAN FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)	156